Whitehawk Therapeutics (WHWK) vs. The Competition Head-To-Head Contrast

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 450 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Whitehawk Therapeutics to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares Whitehawk Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	-40.17
Whitehawk Therapeutics Competitors	$439.20 million	-$68.89 million	-9.35

Whitehawk Therapeutics’ rivals have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Whitehawk Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ rivals have a beta of 10.34, suggesting that their average share price is 934% more volatile than the S&P 500.

Profitability

This table compares Whitehawk Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-75.99%	-68.57%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.63%	-43.39%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Whitehawk Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4790	9961	15994	370	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 102.38%. Given Whitehawk Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics has less favorable growth aspects than its rivals.

Summary

Whitehawk Therapeutics rivals beat Whitehawk Therapeutics on 8 of the 13 factors compared.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.